FY2028 EPS Estimates for Clene Inc. (NASDAQ:CLNN) Boosted by Analyst

Clene Inc. (NASDAQ:CLNN) – Equities research analysts at Roth Capital increased their FY2028 EPS estimates for shares of Clene in a research report issued to clients and investors on Wednesday, May 8th. Roth Capital analyst J. Aschoff now expects that the company will post earnings of $0.91 per share for the year, up from their previous estimate of $0.87. The consensus estimate for Clene’s current full-year earnings is ($0.33) per share.

Other analysts also recently issued reports about the company. HC Wainwright reiterated a “buy” rating and issued a $7.00 price target on shares of Clene in a report on Wednesday. Benchmark reaffirmed a “buy” rating and set a $5.00 price target on shares of Clene in a report on Wednesday, March 20th.

Clene Stock Up 0.8 %

NASDAQ CLNN traded up $0.00 during trading hours on Friday, hitting $0.39. The company had a trading volume of 300,297 shares, compared to its average volume of 914,125. Clene has a fifty-two week low of $0.25 and a fifty-two week high of $1.09. The company has a market capitalization of $50.09 million, a price-to-earnings ratio of -0.74 and a beta of 0.47. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.53 and a quick ratio of 1.53. The firm’s 50 day moving average is $0.40 and its 200 day moving average is $0.41.

Clene (NASDAQ:CLNN) last posted its earnings results on Wednesday, March 13th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.01. Clene had a negative net margin of 7,569.42% and a negative return on equity of 253.48%. The firm had revenue of $0.17 million during the quarter, compared to the consensus estimate of $0.14 million.

Institutional Investors Weigh In On Clene

A hedge fund recently bought a new stake in Clene stock. Csenge Advisory Group acquired a new position in shares of Clene Inc. (NASDAQ:CLNN) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 116,600 shares of the company’s stock, valued at approximately $58,000. Csenge Advisory Group owned 0.09% of Clene as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 23.28% of the company’s stock.

About Clene

Clene Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.